2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced CancerâA Phase 1 Study
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang C, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced CancerâA Phase 1 Study. JAMA Oncology 2019, 5: 1332-1339. PMID: 31154457, PMCID: PMC6547135, DOI: 10.1001/jamaoncol.2019.2244.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaSafety of pembrolizumabB-cell lymphoproliferationCells/ÎŒLAntiretroviral therapyTumor responseKaposi's sarcomaStable diseaseCD4 countAdverse eventsAdvanced cancerMost treatment-emergent adverse eventsAdverse Events grade 2Anti-PD-1 therapyNCI Common Terminology CriteriaTreatment-emergent adverse eventsActive immunosuppressive therapyCommon Terminology CriteriaGood tumor responseT-cell countsAlanine aminotransferase levelsHIV viral loadPhase 1 studyImmune-related eventsCopies/mL
2017
OP8.3 Interim safety analysis of cancer immunotherapy trials Network â 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer
Uldrick T, Cheever M, Gonçalves P, Fling S, Aleman K, Emu B, Ernstoff M, Gorelick R, Kaiser J, Kohrt H, Lacroix A, Lindsley M, Lundgren L, Lurain K, Maldarelli F, Parsons C, Sharon E, Widell A, Yarchoan R. OP8.3 Interim safety analysis of cancer immunotherapy trials Network â 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer. Journal Of Virus Eradication 2017, 3: 55-56. DOI: 10.1016/s2055-6640(20)30567-7.Peer-Reviewed Original Research